
Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
Independent pharmacies' constant battle over the years to try and get relief for NCPA members on these retroactive DIR fees have been really the number one issue.
Today's episode features Ronna Hauser and Karry La Violette from NCPA who discuss the most recent rules from CMS and how it will impact DIR fees in the pharmacy landscape.






